

Susan A. Cantrell Chief Executive Officer, AMCP

SEPTEMBER 20-21 CALIFORNIA AFFILIATE DAY OF EDUCATION



1

Today's Discussion

AMCP Mission, Members Strategic Priorities Trends in Managed Care Pharmacy Key Events & Initiatives

FUTURE OF AMCP AND MANAGED CARE IN THE US CALIFORNIA AFFILIATE DAY OF EDUCATION






Mission

To improve patient health by ensuring access to high-quality, cost-effective medications and other therapies.

FUTURE OF AMCP AND MANAGED CARE IN THE US CALIFORNIA AFFILIATE DAY OF EDUCATION

МСР





Strategic Initiative Optimize Value & Access	Strategic Initiative Address Disparities In Medication Use & Access	Strategic Initiative Amplify AMCP Value & Voice	Strategic Initiative Drive AMCP Performance
Overarching Goal Help members and stakeholders improve healthcare access, affordability, and outcomes	Overarching Goal Address barriers to access and the effective use of medications and other therapies	Overarching Goal Grow our membership and make AMCP essential to those involved in managed care pharmacy	Overarching Goal Maximize effectiveness to achieve optimal results
 Areas of Focus Provide resources to help payers evaluate digital therapeutics Promote the adoption of biosimilars Provide tools to incorporate the patient perspective into formulary decision making Evaluate the implications of measures to reduce drug costs, including the Inflation Reduction Act. 	 Areas of Focus Create awareness and identify opportunities to mitigate disparities in medication use from a managed care perspective Provide tools to incorporate the patient perspective into healthcare decision-making Encourage research into disparities in medication use 	 Areas of Focus Engage and retain members and elevate their voice and impact Build awareness of AMCP and managed care pharmacy and grow membership Build an organization that is #AMCPmember1st 	Areas of Focus Financial Performance Membership Performance Operational Excellence Thought Leadership Exceptional Governance



A LOT. АМСР

FUTURE OF AMCP AND MANAGED CARE IN THE US CALIFORNIA AFFILIATE DAY OF EDUCATION

U.S. health care spending







Source: https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/historical



of GDP



covered by health insurance



AMCP

FUTURE OF AMCP AND MANAGED CARE IN THE US CALIFORNIA AFFILIATE DAY OF EDUCATION

Rising pharmaceutical expenditures

The median annual price for new drugs approved by FDA increased from \$180K in 2021 to \$300K in 2023

6.7 Billion

Prescriptions dispensed in 2022



Innovation

50-55 new products per year projected Will contribute \$133 billion in spending growth by 2025



FUTURE OF AMCP AND MANAGED CARE IN THE US CALIFORNIA AFFILIATE DAY OF EDUCATION

Source: IQVIA, The use of medicines in the U.S. 2023 PWC, Medical cost trend: Behind the numbers 2024, Reuters, Prices for New Drugs Rose 35% in 2023.

\$103 Billion

Increase in total drug spending over past five years




\$82 Billion


Patient out-of-pocket costs








































<section-header><text><list-item><list-item><list-item><list-item><list-item>



Slide 22

RS0 [@Erica Klinger] - we have done some education on AI at the last few meetings, and we will have a session at Nexus titled, "The Artificial Intelligence Frontier: Navigating Data-Driven Formulary Decisions". I am not sure if we need to discuss policies we've implemented or the Board discussion. We are planning more in 2025, but not sure we are ready to announce. I also think MCP is looking at ways to leverage AI like in prior authorizations, etc things we can showcase in the future.

Ruby Singh, 2024-09-17T12:48:17.055




PBM legislation: common proposals

- Reporting Increasing PBM reporting to health plan sponsors and the Federal Government
- Anti-Spread Pricing Prohibits PBMs from charging an amount for a drug's ingredient cost or dispensing fee that is different from the amount reimbursed to a pharmacy
- **Rebate Pass-Through** PBMs would pass on 100% of rebates, fees, alternative discounts, and other remuneration to plan sponsors
- Limiting Administrative Fees Limits PBMs to charging administrative fees that are flat, fee-based, "reasonable," and/or delinked from the cost of a drug
- **Anti-Steering** Prohibits PBMs from compensating a network pharmacy less than affiliated pharmacies

FUTURE OF AMCP AND MANAGED CARE IN THE US CALIFORNIA AFFILIATE DAY OF EDUCATION


AMCP

<section-header><list-item><list-item><list-item><list-item><list-item><list-item><list-item>









AMCP Legislative & Regulatory Position: Pharmacy Benefit Managers

Legislative and Regulatory Position Statement:

In our efforts to foster greater access and affordability to health care across America, AMCP supports a wide range of measures that strike a balance between market-oriented principles and prudent regulations. Pharmacy benefit managers (PBMs) help facilitate patient access to medication at an affordable price. As of January 2023, approximately 275 million Americans received pharmacy benefits administered by PBMs.¹ PBMs contract with a variety of payers, including benefit plan sponsors, insurers, employers, labor unions, and government programs, to oversee the prescription drug portion of health care benefits. They may also engage in a variety of support functions, such as creating formularies, negotiating manufacturer rebates, processing prescription drug claims, managing pharmacy networks, and reviewing drug utilization.

https://www.amcp.org/legislative-regulatory-position/pharmacy-benefit-managers

FUTURE OF AMCP AND MANAGED CARE IN THE US CALIFORNIA AFFILIATE DAY OF EDUCATION



AMCP

AMCP

Chevron deference overturned: impact on regulatory law

The Supreme Court's Loper Bright decision (June 2024) ends 40 years of Chevron deference, limiting agencies' power to interpret ambiguous statutes.

- **1. Increased Litigation:** More industry challenges to new regulations, particularly in healthcare (CMS, FDA).
- 2. Regulatory Uncertainty: Court decisions will now vary across jurisdictions, complicating industry compliance.
- **3. Cautious Rulemaking:** Agencies may slow policy development, impacting sectors like drug and device approvals.

FUTURE OF AMCP AND MANAGED CARE IN THE US CALIFORNIA AFFILIATE DAY OF EDUCATION

